Comparison
Lion's Mane vs PT-141
Side-by-side of Lion's Mane and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Lion's Mane
Lion's mane mushroom (Hericium erinaceus) supplement profile: hericenones and erinacines stimulate NGF in vitro. Human cognition trials are small.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
Lion's Mane
- •Edible medicinal mushroom containing NGF-stimulating hericenones and erinacines
- •Mori 2009 trial (n=30) in mild cognitive impairment showed cognitive improvement at 3 g/day for 16 weeks, reversing 4 weeks after discontinuation
- •Saitsu 2019 (n=31) in older adults reported MoCA improvements at 3.2 g/day over 12 weeks
- •Multiple small mood trials suggest reduced anxiety and depression scores at 1 to 4 g/day extract
- •Mechanistic case rests on NGF stimulation and remyelination support; in vivo human NGF measurement is absent
- •Product quality varies substantially; mycelium-on-grain products can be over 50% grain by weight
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | Lion's Mane | PT-141 |
|---|---|---|
| Category | natural | peptide |
| Also known as | Hericium erinaceus, Yamabushitake, Bearded Tooth, Hou Tou Gu | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 6 | 2.7 |
| Typical dose (mg) ↗ | 1000 | 1.75 |
| Dosing frequency | 1 to 2 times daily | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral | subcutaneous |
| Onset (hr) | 168 | 0.75 |
| Peak (hr) | 1344 | 1.5 |
| Molecular weight | - | 1025.18 |
| Molecular formula | mixed extract | C50H68N14O10 |
| Mechanism | Hericenones and erinacines stimulate NGF mRNA expression and NGF protein release in cultured neurons; secondary anti-inflammatory and remyelination-supportive activity in preclinical models. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | Dietary supplement and food worldwide; unscheduled and unrestricted | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement and food | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Insufficient data for routine supplementation; consumed historically as food without documented harm | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | 189691-06-3 | |
| PubChem CID | 9941379 | |
| Wikidata | Q146050 | Q422059 |
Safety profile
Lion's Mane
Common side effects
- mild GI upset
- occasional skin rash
- contact dermatitis (rare)
Contraindications
- mushroom allergy
Interactions
- anticoagulants: theoretical antiplatelet effect, no documented clinical events(minor)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
Lion's Mane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Lion's Mane.
- → If your priority is nerve health, pick Lion's Mane.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you want to avoid research-only / gray-market sourcing, Lion's Mane is the more accessible choice.
Default choice: Lion's Mane. Lower friction to source, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Lion's Mane and PT-141?
Lion's Mane and PT-141 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Lion's Mane or PT-141?
Lion's Mane half-life is 6 hours; PT-141 half-life is 2.7 hours.
Can you stack Lion's Mane with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper